Vietnam Clinical Nutrition for Chronic Kidney Diseases Market Analysis

Vietnam Clinical Nutrition for Chronic Kidney Diseases Market Executive Summary

Vietnam Clinical Nutrition for Chronic Kidney Diseases Market was valued at $7.80 Mn in 2023 and is predicted to grow at a CAGR of 6.26% from 2023 to 2030, to $12 Mn by 2030. 

Chronic kidney disease (CKD) is a gradual loss of kidney function over at least three months, often progressing silently due to the absence of early symptoms. Main causes include diabetes and high blood pressure, though family history and other conditions also contribute. As CKD advances through stages, it may necessitate dialysis or a kidney transplant and is associated with increased risks of heart disease, stroke, and bone issues. Management focuses on slowing disease progression, symptom management, and preventing complications through dietary changes, medications, and blood pressure control. Key dietary adjustments include moderating protein intake, managing fluid levels, controlling electrolytes like sodium, potassium, and phosphorus, and ensuring sufficient calorie intake to avoid malnutrition. Early detection and screening are crucial for those at risk.

Chronic kidney disease (CKD) is a significant health concern in Vietnam, with an estimated 8,000 new cases annually and over 10 Mn affected individuals. Treatment costs are substantial, as evidenced by a 2019 study at District 2 Hospital in Ho Chi Minh City, which reported total expenses for CKD patients reaching approximately USD 916.42 Mn. Despite the financial burden of CKD care exceeding Vietnam’s per capita GDP, especially during the initial stages, the disease remains underdiagnosed and undertreated, with up to 9,000 new cases annually receiving inadequate attention.

The market therefore is driven by significant factors like rising chronic disease burden, aging population, and technological advancements. However, limited awareness, healthcare infrastructure, and cost concerns restrict the growth and potential of the market.

Prominent players in this field are Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

Market Dynamics

Market Growth Drivers

Rising Chronic Disease Burden: The increase in chronic diseases like diabetes in Vietnam is a major driver for the CKD clinical nutrition market. As diabetes is a leading cause of CKD, the rising number of diabetes cases leads to a higher demand for specialized nutritional products to manage CKD effectively.

Aging Population: Vietnam's aging population, vulnerable to CKD, spurs demand for medical nutrition solutions. As of 2019, those aged 60 and above constitute over 11.9% of the total population, emphasizing the need for targeted healthcare interventions.

Technological Advancements: Innovations in clinical nutrition, such as specialized formulas and personalized nutrition plans, enhance patient outcomes and attract more users. Technological progress in creating and delivering these products supports market growth by meeting the specific dietary needs of CKD patients.

Market Restraints

Limited Awareness: Many Vietnamese are not aware of the benefits of clinical nutrition in managing CKD, which limits the market's growth. Public education and healthcare provider training are needed to increase understanding and adoption of nutritional interventions for CKD.

Healthcare Infrastructure: The uneven distribution of qualified dietitians and specialized renal care facilities, especially in rural areas, restricts access to proper CKD nutritional support. Improving healthcare infrastructure and resource distribution is essential to provide adequate care across the country.

Cost Concerns: The high cost of medical nutrition products and consultations can be a barrier for many patients, particularly in low-income and rural areas. Addressing affordability through subsidies, insurance, and cost-effective products is crucial to making these nutritional supports accessible to more people.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape for clinical nutrition products in Vietnam is managed by the Ministry of Health (MOH), requiring all medical nutrition products, including those for CKD, to undergo a rigorous registration process. This involves submitting detailed product information, scientific data, and manufacturing details for approval. Additionally, labelling and advertising are strictly regulated to ensure accuracy and prevent misleading claims. Manufacturers and distributors must comply with these regulations to guarantee the safety and efficacy of their products. Given the complexity and evolving nature of these regulations, consulting with a specialist in Vietnamese medical device regulations is advisable for the most current information.

The reimbursement scenario for clinical nutrition products in Vietnam is still developing, with public health insurance currently offering limited coverage for specialized medical nutrition products for CKD. As a result, patients often face significant out-of-pocket costs, which can affect affordability and access to these essential products. However, there is potential for growth as the government increasingly recognizes the importance of medical nutrition therapy. Future healthcare policy developments may improve reimbursement options for CKD-specific nutritional products, enhancing market access and patient support.

Competitive Landscape

Key Players

Here are some of the major key players in the Vietnam Clinical Nutrition for Chronic Kidney Diseases Market

• Abbott Nutrition
• Pfizer Inc.
• Bayer AG
• Nestlé Health Science
• Otsuka Pharmaceutical
• Mead Johnson & Company, LLC
• Danone S.A.
• Victus, Inc.
• B. Braun Melsungen AG
• Fresenius Kabi AG